Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: Intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate
Intensive high-flux hemodiafiltration is often used in the management of vancomycin toxicity. We describe two patients who developed hypophosphatemia as a consequence of this form of therapy. The first patient was treated with an intravenous phosphorus infusion. For the second patient, hypophosphate...
Gespeichert in:
Veröffentlicht in: | American journal of kidney diseases 2000-12, Vol.36 (6), p.1262-1266 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1266 |
---|---|
container_issue | 6 |
container_start_page | 1262 |
container_title | American journal of kidney diseases |
container_volume | 36 |
creator | Gatchalian, Raul A. Popli, Ajay Ejaz, Abutaleb A. Leehey, David J. Kjellstrand, Carl M. Ing, Todd S. |
description | Intensive high-flux hemodiafiltration is often used in the management of vancomycin toxicity. We describe two patients who developed hypophosphatemia as a consequence of this form of therapy. The first patient was treated with an intravenous phosphorus infusion. For the second patient, hypophosphatemia was corrected, during hemodiafiltration, with the use of a phosphorus-enriched dialysate. The latter dialysate was prepared by adding sodium phosphate salts to the “base concentrate” of a dual-concentrate, bicarbonate-based dialysate delivery system. This simple method was more efficient than intravenous therapy in ameliorating the hypophosphatemia secondary to aggressive hemodiafiltration treatment. |
doi_str_mv | 10.1053/ajkd.2000.19843 |
format | Article |
fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1053_ajkd_2000_19843</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0272638600700977</els_id><sourcerecordid>11096051</sourcerecordid><originalsourceid>FETCH-LOGICAL-c371t-cbb9f7dcc34562fd51cb189d9e3fdf7bdfc3e5f96eb72282bf2e722a458e6a7e3</originalsourceid><addsrcrecordid>eNp1kU9v1DAQxS0EokvhzA1Z4pw2tjdOwg1VhVZqxaU9RxN73LgkdmQ7q-a78eHwdpc_l548I_3ezPM8Qj6y8oyVlTiHx5_6jJdlbttmK16RDau4KGQjmtdkU_KaF1I08oS8i_ExY62Q8i05YaxsZVmxDfl1Cw4ecEKXqDd0WGc_Dz7OAyScLFDr9KJQ036lg30YCjMuT3TAyWsLxo4pQLLeUeMDTQPSFBDSn2E7cMpPq7KOJv9klU3rF3rtsmaHzi-RHjb5kMssDjCvdIch5naJuJ8A_yEFumDVkL3k1eMas8H35I2BMeKH43tK7r9d3l1cFTc_vl9ffL0plKhZKlTft6bWSoltJbnRFVM9a1rdojDa1L02SmBlWol9zXnDe8MxF7CtGpRQozgl54e5KvgYA5puDnaCsHas7PY5dPscun0O3XMOWfHpoJiXfkL9jz8ePgOfjwBEBaMJ-VY2_uUaLgXfZqo9UJh_t7MYuqgsuhyIDahSp7190cJvB_ysLw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: Intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Gatchalian, Raul A. ; Popli, Ajay ; Ejaz, Abutaleb A. ; Leehey, David J. ; Kjellstrand, Carl M. ; Ing, Todd S.</creator><creatorcontrib>Gatchalian, Raul A. ; Popli, Ajay ; Ejaz, Abutaleb A. ; Leehey, David J. ; Kjellstrand, Carl M. ; Ing, Todd S.</creatorcontrib><description>Intensive high-flux hemodiafiltration is often used in the management of vancomycin toxicity. We describe two patients who developed hypophosphatemia as a consequence of this form of therapy. The first patient was treated with an intravenous phosphorus infusion. For the second patient, hypophosphatemia was corrected, during hemodiafiltration, with the use of a phosphorus-enriched dialysate. The latter dialysate was prepared by adding sodium phosphate salts to the “base concentrate” of a dual-concentrate, bicarbonate-based dialysate delivery system. This simple method was more efficient than intravenous therapy in ameliorating the hypophosphatemia secondary to aggressive hemodiafiltration treatment.</description><identifier>ISSN: 0272-6386</identifier><identifier>EISSN: 1523-6838</identifier><identifier>DOI: 10.1053/ajkd.2000.19843</identifier><identifier>PMID: 11096051</identifier><language>eng</language><publisher>Orlando, FL: Elsevier Inc</publisher><subject>Adult ; Aged ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Anti-Bacterial Agents - poisoning ; Anti-Bacterial Agents - therapeutic use ; Biological and medical sciences ; dialysate ; Dialysis Solutions - administration & dosage ; Drug Overdose - therapy ; Emergency and intensive care: renal failure. Dialysis management ; Hemodiafiltration - adverse effects ; high-flux hemodiafiltration ; Humans ; Hypophosphatemia ; Hypophosphatemia - drug therapy ; Hypophosphatemia - etiology ; Hypophosphatemia - therapy ; Infusions, Intravenous ; Intensive care medicine ; Male ; Medical sciences ; Methicillin Resistance ; nephrotoxicity ; phosphorus ; Phosphorus - administration & dosage ; Phosphorus - therapeutic use ; Staphylococcal Infections - drug therapy ; vancomycin ; Vancomycin - poisoning ; Vancomycin - therapeutic use</subject><ispartof>American journal of kidney diseases, 2000-12, Vol.36 (6), p.1262-1266</ispartof><rights>2000 National Kidney Foundation, Inc</rights><rights>2001 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c371t-cbb9f7dcc34562fd51cb189d9e3fdf7bdfc3e5f96eb72282bf2e722a458e6a7e3</citedby><cites>FETCH-LOGICAL-c371t-cbb9f7dcc34562fd51cb189d9e3fdf7bdfc3e5f96eb72282bf2e722a458e6a7e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1053/ajkd.2000.19843$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27929,27930,46000</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=826324$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11096051$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gatchalian, Raul A.</creatorcontrib><creatorcontrib>Popli, Ajay</creatorcontrib><creatorcontrib>Ejaz, Abutaleb A.</creatorcontrib><creatorcontrib>Leehey, David J.</creatorcontrib><creatorcontrib>Kjellstrand, Carl M.</creatorcontrib><creatorcontrib>Ing, Todd S.</creatorcontrib><title>Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: Intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate</title><title>American journal of kidney diseases</title><addtitle>Am J Kidney Dis</addtitle><description>Intensive high-flux hemodiafiltration is often used in the management of vancomycin toxicity. We describe two patients who developed hypophosphatemia as a consequence of this form of therapy. The first patient was treated with an intravenous phosphorus infusion. For the second patient, hypophosphatemia was corrected, during hemodiafiltration, with the use of a phosphorus-enriched dialysate. The latter dialysate was prepared by adding sodium phosphate salts to the “base concentrate” of a dual-concentrate, bicarbonate-based dialysate delivery system. This simple method was more efficient than intravenous therapy in ameliorating the hypophosphatemia secondary to aggressive hemodiafiltration treatment.</description><subject>Adult</subject><subject>Aged</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Anti-Bacterial Agents - poisoning</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>dialysate</subject><subject>Dialysis Solutions - administration & dosage</subject><subject>Drug Overdose - therapy</subject><subject>Emergency and intensive care: renal failure. Dialysis management</subject><subject>Hemodiafiltration - adverse effects</subject><subject>high-flux hemodiafiltration</subject><subject>Humans</subject><subject>Hypophosphatemia</subject><subject>Hypophosphatemia - drug therapy</subject><subject>Hypophosphatemia - etiology</subject><subject>Hypophosphatemia - therapy</subject><subject>Infusions, Intravenous</subject><subject>Intensive care medicine</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Methicillin Resistance</subject><subject>nephrotoxicity</subject><subject>phosphorus</subject><subject>Phosphorus - administration & dosage</subject><subject>Phosphorus - therapeutic use</subject><subject>Staphylococcal Infections - drug therapy</subject><subject>vancomycin</subject><subject>Vancomycin - poisoning</subject><subject>Vancomycin - therapeutic use</subject><issn>0272-6386</issn><issn>1523-6838</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kU9v1DAQxS0EokvhzA1Z4pw2tjdOwg1VhVZqxaU9RxN73LgkdmQ7q-a78eHwdpc_l548I_3ezPM8Qj6y8oyVlTiHx5_6jJdlbttmK16RDau4KGQjmtdkU_KaF1I08oS8i_ExY62Q8i05YaxsZVmxDfl1Cw4ecEKXqDd0WGc_Dz7OAyScLFDr9KJQ036lg30YCjMuT3TAyWsLxo4pQLLeUeMDTQPSFBDSn2E7cMpPq7KOJv9klU3rF3rtsmaHzi-RHjb5kMssDjCvdIch5naJuJ8A_yEFumDVkL3k1eMas8H35I2BMeKH43tK7r9d3l1cFTc_vl9ffL0plKhZKlTft6bWSoltJbnRFVM9a1rdojDa1L02SmBlWol9zXnDe8MxF7CtGpRQozgl54e5KvgYA5puDnaCsHas7PY5dPscun0O3XMOWfHpoJiXfkL9jz8ePgOfjwBEBaMJ-VY2_uUaLgXfZqo9UJh_t7MYuqgsuhyIDahSp7190cJvB_ysLw</recordid><startdate>20001201</startdate><enddate>20001201</enddate><creator>Gatchalian, Raul A.</creator><creator>Popli, Ajay</creator><creator>Ejaz, Abutaleb A.</creator><creator>Leehey, David J.</creator><creator>Kjellstrand, Carl M.</creator><creator>Ing, Todd S.</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20001201</creationdate><title>Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: Intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate</title><author>Gatchalian, Raul A. ; Popli, Ajay ; Ejaz, Abutaleb A. ; Leehey, David J. ; Kjellstrand, Carl M. ; Ing, Todd S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c371t-cbb9f7dcc34562fd51cb189d9e3fdf7bdfc3e5f96eb72282bf2e722a458e6a7e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Anti-Bacterial Agents - poisoning</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>dialysate</topic><topic>Dialysis Solutions - administration & dosage</topic><topic>Drug Overdose - therapy</topic><topic>Emergency and intensive care: renal failure. Dialysis management</topic><topic>Hemodiafiltration - adverse effects</topic><topic>high-flux hemodiafiltration</topic><topic>Humans</topic><topic>Hypophosphatemia</topic><topic>Hypophosphatemia - drug therapy</topic><topic>Hypophosphatemia - etiology</topic><topic>Hypophosphatemia - therapy</topic><topic>Infusions, Intravenous</topic><topic>Intensive care medicine</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Methicillin Resistance</topic><topic>nephrotoxicity</topic><topic>phosphorus</topic><topic>Phosphorus - administration & dosage</topic><topic>Phosphorus - therapeutic use</topic><topic>Staphylococcal Infections - drug therapy</topic><topic>vancomycin</topic><topic>Vancomycin - poisoning</topic><topic>Vancomycin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gatchalian, Raul A.</creatorcontrib><creatorcontrib>Popli, Ajay</creatorcontrib><creatorcontrib>Ejaz, Abutaleb A.</creatorcontrib><creatorcontrib>Leehey, David J.</creatorcontrib><creatorcontrib>Kjellstrand, Carl M.</creatorcontrib><creatorcontrib>Ing, Todd S.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>American journal of kidney diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gatchalian, Raul A.</au><au>Popli, Ajay</au><au>Ejaz, Abutaleb A.</au><au>Leehey, David J.</au><au>Kjellstrand, Carl M.</au><au>Ing, Todd S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: Intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate</atitle><jtitle>American journal of kidney diseases</jtitle><addtitle>Am J Kidney Dis</addtitle><date>2000-12-01</date><risdate>2000</risdate><volume>36</volume><issue>6</issue><spage>1262</spage><epage>1266</epage><pages>1262-1266</pages><issn>0272-6386</issn><eissn>1523-6838</eissn><abstract>Intensive high-flux hemodiafiltration is often used in the management of vancomycin toxicity. We describe two patients who developed hypophosphatemia as a consequence of this form of therapy. The first patient was treated with an intravenous phosphorus infusion. For the second patient, hypophosphatemia was corrected, during hemodiafiltration, with the use of a phosphorus-enriched dialysate. The latter dialysate was prepared by adding sodium phosphate salts to the “base concentrate” of a dual-concentrate, bicarbonate-based dialysate delivery system. This simple method was more efficient than intravenous therapy in ameliorating the hypophosphatemia secondary to aggressive hemodiafiltration treatment.</abstract><cop>Orlando, FL</cop><pub>Elsevier Inc</pub><pmid>11096051</pmid><doi>10.1053/ajkd.2000.19843</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0272-6386 |
ispartof | American journal of kidney diseases, 2000-12, Vol.36 (6), p.1262-1266 |
issn | 0272-6386 1523-6838 |
language | eng |
recordid | cdi_crossref_primary_10_1053_ajkd_2000_19843 |
source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
subjects | Adult Aged Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Anti-Bacterial Agents - poisoning Anti-Bacterial Agents - therapeutic use Biological and medical sciences dialysate Dialysis Solutions - administration & dosage Drug Overdose - therapy Emergency and intensive care: renal failure. Dialysis management Hemodiafiltration - adverse effects high-flux hemodiafiltration Humans Hypophosphatemia Hypophosphatemia - drug therapy Hypophosphatemia - etiology Hypophosphatemia - therapy Infusions, Intravenous Intensive care medicine Male Medical sciences Methicillin Resistance nephrotoxicity phosphorus Phosphorus - administration & dosage Phosphorus - therapeutic use Staphylococcal Infections - drug therapy vancomycin Vancomycin - poisoning Vancomycin - therapeutic use |
title | Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: Intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T14%3A21%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Management%20of%20hypophosphatemia%20induced%20by%20high-flux%20hemodiafiltration%20for%20the%20treatment%20of%20vancomycin%20toxicity:%20Intravenous%20phosphorus%20therapy%20versus%20use%20of%20a%20phosphorus-enriched%20dialysate&rft.jtitle=American%20journal%20of%20kidney%20diseases&rft.au=Gatchalian,%20Raul%20A.&rft.date=2000-12-01&rft.volume=36&rft.issue=6&rft.spage=1262&rft.epage=1266&rft.pages=1262-1266&rft.issn=0272-6386&rft.eissn=1523-6838&rft_id=info:doi/10.1053/ajkd.2000.19843&rft_dat=%3Cpubmed_cross%3E11096051%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/11096051&rft_els_id=S0272638600700977&rfr_iscdi=true |